Gossamer Bio, Inc.: Business Overview, Financials & Competitive Analysis
Gossamer Bio, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). High-risk clinical-stage biotech with potential upside if FDA approves seralutinib despite missed primary endpoint, but significant downside if regulatory path narrows. Gossamer Bio exhibits mixed fundamentals: solid liquidity and cash position supporting 1-2 years of runway, but faces critical near-term regulatory hurdle after missing primary PROSERA endpoint. Strong analyst.
What is Gossamer Bio, Inc.'s industry? Gossamer Bio, Inc. (gossamerbio.com) operates in Biopharmaceuticals - Rare/Orphan Pulmonary Diseases. AskCyborg classifies Gossamer Bio, Inc. under Biopharmaceuticals - Rare/Orphan Pulmonary Diseases in its company registry.
Gossamer Bio is a late-stage clinical biopharmaceutical company focused on developing seralutinib for rare pulmonary diseases, specifically pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w...
Cyborg Score thesis
High-risk clinical-stage biotech with potential upside if FDA approves seralutinib despite missed primary endpoint, but...
Read the full analyst-debate transcript →Get the Latest Gossamer Bio, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeGossamer Bio, Inc. Overview
Pro stress-test →Gossamer Bio is a late-stage clinical biopharmaceutical company focused on developing seralutinib for rare pulmonary diseases, specifically pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company recently announced Phase 3 PROSERA trial results that narrowly missed the primary efficacy endpoint but showed benefit in key subgroups.
Strategic Profile
Pro stress-test →The company is pursuing a focused development strategy with seralutinib as its lead candidate, jointly developed with the Chiesi Group. Gossamer maintains solid cash position (~$180M) but faces regulatory uncertainty following the PROSERA trial outcome, with plans to engage FDA on path forward. The company also has a pipeline including GB004 (IBD), GB001 (eosinophilic asthma), and GB1275 (oncology).
Competitive Landscape
Pro stress-test →Gossamer Bio competes in rare/orphan pulmonary disease space against established PAH players (Actelion/Janssen, United Therapeutics, Gilead) and emerging biotech competitors. The company's focused pipeline approach (seralutinib as lead) contrasts with competitors' broader PAH portfolios. Limited direct competition in PH-ILD segment creates differentiation opportunity, though PROSERA trial setback weakens near-term competitive positioning versus established therapies.
Industry Context
Gossamer Bio, Inc. operates in Biopharmaceuticals - Rare/Orphan Pulmonary Diseases.
Key facts
Headquarters: San Diego, US · Revenue: $44.1M · Market cap: $561M